Modulation of Stat3 Alternative Splicing in Breast Cancer
Abstract
Stat3 is a transcription factor constitutively active in a large number of breast cancers and other tumors, where it works as a central player in the activation of multiple oncogenic pathways. We developed a method to modulate endogenous Stat3 alternative splicing using modified antisense oligonucleotides, to induce the dominant negative Stat3-beta variant in vitro and in vivo. Switching from the full length Stat3 isoform to the stat3-beta variant leads to increased tumor cell death and complete tumor regression in animal models via a novel modulatory mechanism.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2010
- Accession Number
- ADA549137
Entities
People
- Luca Cartegni
Organizations
- Memorial Sloan Kettering Cancer Center